Stifel analyst Dae Gon Ha raised the firm’s price target on Krystal Biotech to $220 from $204 and keeps a Buy rating on the shares. In conjunction with the firm’s deep dive on alpha-1 antitrypsin deficiency, or AATD, the analyst is updating models to better reflect revenue contributions from three competitors’ respective AATD assets. The firm expects KB408 commercialization in 2029 in the U.S. and 2030 in the EU to precede gene editing approaches’ launch in 2030 and 2031, respectively.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Beam Therapeutics price target raised to $69 from $66 at Stifel
- Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Krystal Biotech price target raised to $205 from $195 at BofA
- Krystal Biotech Reports Promising KB301 Phase 1 Results
- Krystal Biotech price target raised to $221 from $200 at H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com